News and Events

Emerillon Capital and Sanderling Ventures Join Forces Backing a New Precision Medicine Company Based in Montreal, Canada

Montreal – May. 10th, 2017 – Emerillon Capital and Sanderling Ventures announced they are joining forces to finance PreciThera Inc, an emerging Montreal based precision medicine company dedicated to the design and the development of innovative biological agents for the treatment of orphan diseases. PreciThera was….

Read More

Therillia Names Dr. Pierre Beauparlant Chief Business Officer

Montreal – Dec. 5th, 2016 – Therillia Development Company Inc., a Sanderling Ventures portfolio company, announced today the appointment of Dr. Pierre Beauparlant as Chief Business Officer. He will be responsible for the development and execution of…

Read More

Entrepreneurial Spots – Therillia

On the one side, Dr. Gordon C. Shore, experienced biochemistry professor, member of the Goodman Cancer Research Centre, and director of the Laboratory for Therapeutic Development at McGill University. On the other, Dr. Robert G. McNeil…

Read More